X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Pfizer with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ACTAVIS (US) - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PFIZER   ACTAVIS
EQUITY SHARE DATA
    PFIZER
Mar-18
ACTAVIS
Dec-14
PFIZER/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs2,36519,396-   
Low Rs1,62511,831-   
Sales per share (Unadj.) Rs430.33,492.7-  
Earnings per share (Unadj.) Rs78.7-435.9-  
Cash flow per share (Unadj.) Rs93.2320.4-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs586.57,575.5-  
Shares outstanding (eoy) m45.75265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.64.5 103.7%   
Avg P/E ratio x25.3-35.8 -70.8%  
P/CF ratio (eoy) x21.448.7 43.9%  
Price / Book Value ratio x3.42.1 165.0%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m91,2714,151,646 2.2%   
No. of employees `0002.621.6 12.2%   
Total wages/salary Rs m3,1430-   
Avg. sales/employee Rs Th7,484.842,995.8 17.4%   
Avg. wages/employee Rs Th1,195.00-   
Avg. net profit/employee Rs Th1,369.1-5,365.4 -25.5%   
INCOME DATA
Net Sales Rs m19,685928,708 2.1%  
Other income Rs m1,143-2,318 -49.3%   
Total revenues Rs m20,828926,390 2.2%   
Gross profit Rs m5,003119,306 4.2%  
Depreciation Rs m663201,099 0.3%   
Interest Rs m429,293 0.0%   
Profit before tax Rs m5,479-113,405 -4.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,319 0.0%   
Tax Rs m1,878-5,830 -32.2%   
Profit after tax Rs m3,601-115,893 -3.1%  
Gross profit margin %25.412.8 197.8%  
Effective tax rate %34.35.1 666.8%   
Net profit margin %18.3-12.5 -146.6%  
BALANCE SHEET DATA
Current assets Rs m24,167489,310 4.9%   
Current liabilities Rs m9,544356,851 2.7%   
Net working cap to sales %74.314.3 520.8%  
Current ratio x2.51.4 184.7%  
Inventory Days Days5558 94.9%  
Debtors Days Days2966 43.3%  
Net fixed assets Rs m9,514113,405 8.4%   
Share capital Rs m4580-   
"Free" reserves Rs m26,3750-   
Net worth Rs m26,8322,014,334 1.3%   
Long term debt Rs m251,055,551 0.0%   
Total assets Rs m36,9003,691,612 1.0%  
Interest coverage x1,305.5-2.9 -45,467.9%   
Debt to equity ratio x00.5 0.2%  
Sales to assets ratio x0.50.3 212.1%   
Return on assets %9.8-2.3 -416.5%  
Return on equity %13.4-5.8 -233.2%  
Return on capital %20.4-3.0 -678.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,4660-   
CASH FLOW
From Operations Rs m3,318159,477 2.1%  
From Investments Rs m-2,383-381,850 0.6%  
From Financial Activity Rs m-1,104214,544 -0.5%  
Net Cashflow Rs m-169-7,828 2.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare PFIZER With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare PFIZER With: WYETH LTD  STERLING BIOTECH  NATCO PHARMA  TTK HEALTHCARE  ALEMBIC LTD  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 22, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS